Our team brings a rich background of pharmaceutical, biotechnology and CRO drug development expertise to companies we invest in.
Alek has a diverse background in drug development spanning more than thirty years. Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US-based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific. He subsequently founded Novotech, a Sydney-based contract research organisation working with hundreds of clinical stage biotech companies over a twenty-one year period. Alek holds a BPharm and an MBA from the University of Sydney.
Graeme has a forty-year background in Pharma and Biotech across Europe, USA and Japan. After his pharmacology studies, he held senior R&D roles in the UK and USA in multinational companies such as Roche, GSK and Wellcome Research Laboratories. Graeme was President and CEO of Takeda Ventures, the corporate venture arm of Takeda Pharmaceuticals, a global pharmaceutical company. He is a dealmaker with extensive experience in all aspects of venture capital investing, including exits. Graeme holds a BSc and a PhD in Pharmacology.
Lorna has more than twenty years of experience in private equity and venture capital with roles at EQT, Hermes GPE, Citco, Coller Capital, Ariadne Capital, Actis and BancBoston Capital. She holds a BA in Applied Psychology and is registered with the Chartered Institute of Management Accountants (ACMA).
Robert has a successful background in venture capital and Big Pharma, with companies such as GSK and Eli Lilly. He is a passionate startup entrepeneur with experience in university technology transfer. Robert holds a BSc in Physiology and a PhD in Neurophysiology.
Julia has a thirty-year background in Pharma and CRO, with companies such as Johnson & Johnson, Iqvia and Novotech. She also has experience in clinical nursing and research.
Katie has a strong background in venture capital and the healthcare industry. She has held roles in Health Economics and Market Access and Account Management at Johnson & Johnson. She holds a BMedSc in Medical Science and an MPhil in Bioscience Enterprise from Cambridge University.
Andre has a background in big pharma and research in organisations such as GSK and the Broad Institute of MIT and Harvard. He has a history of working in investment funds, as well as early-stage life science ventures. He holds a BSc in Biochemistry and MPhil in Bioscience Enterprise from Cambridge University.
Diana provides a broad range of support to the ALSA Ventures team. She works collaboratively with individuals across all organisational levels and is responsible for handling administrative duties, facilitating internal and external communication, and increasing efficiency in business operational functions.
Robert brings over 20 years of drug development experience. He is VP of product development at ILC therapeutics. He was previously the Senior Director of Preclinical at MiroBio. Before this, Robert worked at Oxford Biotherapeutics, where he was UK site head and Scientific Director leading the development of their therapeutic antibody programs in immune-oncology and oncology. Previously Rob has been a Group Leader and Scientific Investigator at the MRC Toxicology Unit and Oxford Glycosciences.
Jyoti is a Professor of Functional Proteomics at the Institute of Cancer Research. Her research focuses on developing and implementing novel mass spectrometry, and data analysis approaches for proteome discovery. She is also Head of the Proteomics Facility at the Institute of Cancer Research. Before joining the ICR, Jyoti was Head of Proteomic Mass Spectrometry Platform at the Wellcome Trust Sanger Institute. She was a cofounder of Cellzome AG, which was spun out of GSK.
Professor of Cancer Biology, Kings College London and Principal Group Leader at the Francis Crick Institute. He is an expert on oncogenes – the genes that drive cancer development and has played a vital role in identifying some of these genes, e.g. the transcription factor Myc, and revealing how they fuel the disease. Until May 2022 he was Sir William Dunn Professor and Head of Biochemistry at the University of Cambridge, and prior to that, he was a distinguished professor of cancer research at UCSF. He is a member of the European Molecular Biology Organization, the UK Academy of Medical Sciences, and the Royal Society.
Jasmin is a professor of computational biology at UCL. The Fisher Lab develops computational tools to study the evolution of cancer and its underlying mechanisms to identify personalised treatment. Before joining UCL, Jasmin was a Principal Researcher at Microsoft Research in Cambridge and an Associate Professor in systems Biology at Cambridge University.
In a research career spanning 30 years, Michael has worked across academic, biotech and pharmaceutical industries, specialising in protein and antibody engineering. He was formerly Head of Lead Discovery and Director of Antibody Technologies within GSKs Biopharm R&D unit. Before this, he served in a senior role at Domantis Ltd and has also performed prominent roles for other biotech companies and organisations working in diverse areas such as immunodiagnostics and epigenetics.